Trending Topic

3 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

We are delighted to present the latest edition of touchREVIEWS in Oncology & Haematology. This issue underscores the evolving landscape of cancer therapeutics, showcasing advances across a wide range of malignancies, from haematologic diseases to solid tumours, through novel mechanisms, emerging biomarkers and personalized treatment strategies. We begin with an editorial by Isabela Wen-Chi Chang […]

Benjamin A Weinberg, ASCO GI22: Pivotal Studies in Pancreatic Cancer

8 mins
Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: Mar 8th 2022

touchONCOLOGY were thrilled to speak to Professor Benjamin A Weinberg (Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, USA) to discuss the data from the TRYbeCA-1, KRYSTAL-1 and CISPD3 trials, which were presented at the ASCO Gastrointestinal Cancers Symposium 2022.

Questions

  1. What are the hopes of the new drug delivery mechanism using L-asparaginase to treat advanced pancreatic cancer? 00:15-01:13
  2. Why did the TRYbeCA-1 study fail to meet its primary endpoint? 01:13-02:53
  3. How have KRAS G12C inhibitors impacted clinical practice? 02:53-04:33
  4. What can you conclude from the updated results from the KRYSTAL-1 trial in KRAS G12C+ gastrointestinal cancers Cancers? 04:33-06:13
  5. How do you see the future for drug development in advanced pancreatic cancer? 06:14-08:19

Speaker Disclosure: Benjamin A Weinberg has no conflicts of interest to declare in relation to this video.

Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Sophie Nickelson.

Filmed in coverage of the ASCO Gastrointestinal Cancers Symposium 2022.

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Close Popup